APA (7th ed.) Citation

Bärtsch, M., Fougereau, M., Hielscher, T., Sauer, S., Breitkreutz, I., Jordan, K., . . . Giesen, N. (2021). Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma. Cancers, 13(18), . https://doi.org/10.3390/cancers13184706

Chicago Style (17th ed.) Citation

Bärtsch, Marc-Andrea, et al. "Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or Without Maintenance for Relapsed or Refractory Multiple Myeloma." Cancers 13, no. 18 (2021). https://doi.org/10.3390/cancers13184706.

MLA (9th ed.) Citation

Bärtsch, Marc-Andrea, et al. "Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or Without Maintenance for Relapsed or Refractory Multiple Myeloma." Cancers, vol. 13, no. 18, 2021, https://doi.org/10.3390/cancers13184706.